Ligand Pharmaceuticals Incorporated (LGND)
Jul 2, 2025 - LGND was delisted (reason: merged into PTHS)
113.30
+0.74 (0.66%)
Inactive · Last trade price on Jul 2, 2025
Ligand Pharmaceuticals Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Ligand Pharmaceuticals stock had an average target of 144.71, with a low estimate of 135 and a high estimate of 160.
Price Target: $144.71 (+27.72%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 9, 2025.
Analyst Ratings
The average analyst rating for Ligand Pharmaceuticals stock from 8 stock analysts was "Strong Buy". This means that analysts believed this stock was likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 7 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $142 → $145 | Buy | Maintains | $142 → $145 | +27.98% | May 9, 2025 |
| Stifel | Stifel | Strong Buy Initiates $143 | Strong Buy | Initiates | $143 | +26.21% | Apr 10, 2025 |
| Benchmark | Benchmark | Strong Buy Reiterates $135 | Strong Buy | Reiterates | $135 | +19.15% | Dec 23, 2024 |
| Barclays | Barclays | Buy Maintains $150 → $160 | Buy | Maintains | $150 → $160 | +41.22% | Dec 16, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $141 → $143 | Buy | Maintains | $141 → $143 | +26.21% | Dec 11, 2024 |
Financial Forecast
Revenue This Year
197.90M
from 167.13M
Increased by 18.41%
Revenue Next Year
235.24M
from 197.90M
Increased by 18.87%
EPS This Year
6.22
from -0.22
EPS Next Year
7.13
from 6.22
Increased by 14.62%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 209.8M | 255.3M | 321.2M | ||
| Avg | 197.9M | 235.2M | 276.5M | ||
| Low | 181.4M | 208.8M | 240.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 25.5% | 29.0% | 36.5% | ||
| Avg | 18.4% | 18.9% | 17.5% | ||
| Low | 8.6% | 5.5% | 2.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 6.51 | 7.74 | 9.09 | ||
| Avg | 6.22 | 7.13 | 8.22 | ||
| Low | 5.88 | 6.42 | 7.52 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 24.4% | 27.5% | ||
| Avg | - | 14.6% | 15.2% | ||
| Low | - | 3.2% | 5.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.